NCT04325828View on ClinicalTrials.gov

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 7, 2020

Primary Completion Date

June 9, 2021

Study Completion Date

December 31, 2027

Conditions
Salivary Gland Neoplasms
Interventions
DRUG

Apalutamide

Apalutamide 240 mg (4\*60-mg tablets) will be administered orally once daily with or without food.

DRUG

GnRH Agonist

A stable regimen of goserelin 3.6 mg will be administered as a GnRH agonist.

Trial Locations (7)

104 0045

National Cancer Center Hospital, Chūōku

810 8563

National Hospital Organization Kyushu Medical Center, Fukuoka

573 1191

Kansai Medical University Hospital, Hirakata

791 0280

National Hospital Organization Shikoku Cancer Center, Matsuyama

464 8681

Aichi Cancer Center Hospital, Nagoya

951 8520

Niigata University Medical And Dental Hospital, Niigata

060-8648

Hokkaido University Hospital, Sapporo

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT04325828 - A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma | Biotech Hunter | Biotech Hunter